Development of a SPECT -based three-dimensional treatment planner for radionuclide therapy with iodine -131

Accurate calculation of absorbed dose to target tumors and normal tissues in the body is an important requirement for establishing fundamental dose-response relationships for radioimmunotherapy. Two major obstacles have been the difficulty in obtaining an accurate patient-specific 3-D activity map in-vivo and calculating the resulting absorbed dose. This study investigated a methodology for 3-D internal dosimetry, which integrates the 3-D biodistribution of the radionuclide acquired from SPECT with a dose-point kernel convolution technique to provide the 3-D distribution of absorbed dose. Accurate SPECT images were reconstructed with appropriate methods for noise filtering, attenuation correction, and Compton scatter correction. The SPECT images were converted into activity maps using a calibration phantom. The activity map was convolved with an $\sp{131}$I dose-point kernel using a 3-D fast Fourier transform to yield a 3-D distribution of absorbed dose. The 3-D absorbed dose map was then processed to provide the absorbed dose distribution in regions of interest. This methodology can provide heterogeneous distributions of absorbed dose in volumes of any size and shape with nonuniform distributions of activity. Comparison of the activities quantitated by our SPECT methodology to true activities in an Alderson abdominal phantom (with spleen, liver, and spherical tumor) yielded errors of $-$16.3% to 4.4%. Volume quantitation errors ranged from $-$4.0 to 5.9% for volumes greater than 88 ml. The percentage differences of the average absorbed dose rates calculated by this methodology and the MIRD S-values were 9.1% for liver, 13.7% for spleen, and 0.9% for the tumor. Good agreement (percent differences were less than 8%) was found between the absorbed dose due to penetrating radiation calculated from this methodology and TLD measurement. More accurate estimates of the 3-D distribution of absorbed dose can be used as a guide in specifying the minimum activity to be administered to patients to deliver a prescribed absorbed dose to tumor without exceeding the toxicity limits of normal tissues. ^

Transport of prion protein across the blood-brain barrier.

The cellular form of the prion protein (PrP(c)) is necessary for the development of prion diseases and is a highly conserved protein that may play a role in neuroprotection. PrP(c) is found in both blood and cerebrospinal fluid and is likely produced by both peripheral tissues and the central nervous system (CNS). Exchange of PrP(c) between the brain and peripheral tissues could have important pathophysiologic and therapeutic implications, but it is unknown whether PrP(c) can cross the blood-brain barrier (BBB). Here, we found that radioactively labeled PrP(c) crossed the BBB in both the brain-to-blood and blood-to-brain directions. PrP(c) was enzymatically stable in blood and in brain, was cleared by liver and kidney, and was sequestered by spleen and the cervical lymph nodes. Circulating PrP(c) entered all regions of the CNS, but uptake by the lumbar and cervical spinal cord, hypothalamus, thalamus, and striatum was particularly high. These results show that PrP(c) has bidirectional, saturable transport across the BBB and selectively targets some CNS regions. Such transport may play a role in PrP(c) function and prion replication.

Risk factors for spinal surgical site infection

Background. Surgical site infections (SSI) are one of the most common nosocomial infections in the United States. This study was conducted following an increase in the rate of SSI following spinal procedures at the study hospital. ^ Methods. This study examined patient and hospital associated risk factors for SSI using existing data on patients who had spinal surgery performed at the study hospital between December 2003 and August 2005. There were 59 patients with SSI identified as cases; controls were randomly selected from patients who had spinal procedures performed at the study hospital during the study period, but did not develop infection. Of the 245 original records reviewed, 5% were missing more than half the variables and were eliminated from the data set. A total of 234 patients were included in the final analysis, representing 55 cases and 179 controls. Multivariable analysis was conducted using logistic regression to control for confounding variables. ^ Results. Three variables were found to be significant risk factors for SSI in the study population: presence of comorbidities (odds ratio 3.15, 95% confidence interval 1.20 to 8.26), cut time above the population median of 100 minutes (odds ratio 2.98, 95% confidence interval 1.12 to 5.49), and use of iodine only for preoperative skin antisepsis (odds ratio 0.16, 95% confidence interval 0.06 to 0.45). Several risk factors of specific concern to the study hospital, such as operating room, hospital staff involved in the procedures and workers' compensation status, were not shown to be statistically significant. In addition, multiple factors that have been identified in prior studies, such as method of hair removal, smoking status, or incontinence, were not shown to be statistically significant in this population. ^ Conclusions. This study confirms that increased cut time is a risk for post-operative infection. Use of iodine only was found to decrease risk of infection; further study is recommended in a population with higher usage of chlorhexadine gluconate. Presence of comorbidities at the time of surgery was also found to be a risk factor for infection; however, specific comorbidities were not studied. ^